Radiopharm Theranostics (RADX) director discloses major option grants and shares

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd director Hester Denise Larkin filed an initial ownership report showing direct holdings in ordinary shares and stock options. She holds 644,247 ordinary shares directly. She also holds options to buy ordinary shares, including 275,000 shares at $0.06 per share expiring on August 24, 2026, and larger grants such as 5,333,333 shares at $0.06 per share expiring on September 30, 2029. A December 16, 2024 grant provides 2,666,667 options vesting September 30, 2026 and 2,666,666 vesting September 30, 2027 if she remains a director, alongside additional options at $0.60 per share expiring December 1, 2026.

Insights

Equity compensation analyst

Filing details a sizable option-based equity package for a Radiopharm director.

This Form 3 outlines Hester Denise Larkin’s starting equity position at Radiopharm Theranostics Ltd. It combines current ownership of 644,247 ordinary shares with multiple option grants at exercise prices of $0.06 and $0.60 per share.

The largest block is an option for 5,333,333 underlying ordinary shares at $0.06 expiring on September 30, 2029, reflecting substantial long-term equity exposure. A footnote states that 2,666,667 of these options vest on September 30, 2026 and 2,666,666 vest on September 30, 2027, conditioned on her continuing as a director.

No buy or sell transactions are reported here; it is a baseline statement of beneficial ownership. The mix of immediate share ownership and multi-year vesting options ties a significant portion of her potential upside to Radiopharm’s longer-term share performance.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Larkin Hester Denise

Role Director

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Option (right to buy) — 275,000 shares (Direct); Ordinary Shares — 644,247 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Direct ordinary shares: 644,247 shares Option at $0.06 exp 2026: 275,000 underlying shares at $0.06 Large 2029 $0.06 option grant: 5,333,333 underlying shares at $0.06 +3 more

6 metrics

Direct ordinary shares 644,247 shares Directly held ordinary shares as of Form 3

Option at $0.06 exp 2026 275,000 underlying shares at $0.06 Option expiring August 24, 2026

Large 2029 $0.06 option grant 5,333,333 underlying shares at $0.06 Option expiring September 30, 2029

Vesting 2026 tranche 2,666,667 options Vest on September 30, 2026 if still director

Vesting 2027 tranche 2,666,666 options Vest on September 30, 2027 if still director

$0.60 options exp 2026 627,001 underlying shares at $0.60 One of several tranches expiring December 1, 2026

Key Terms

Option (right to buy), Ordinary Shares, exercise price, expiration date, +1 more

5 terms

Option (right to buy) financial

"security_title": "Option (right to buy)""

Ordinary Shares financial

"underlying_security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"conversion_or_exercise_price": "0.0600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2029-09-30T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"options will vest on September 30, 2026 and 2,666,666 options will vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Larkin Hester Denise

(Last) (First) (Middle)

SUITE 1 LEVEL 3, 62 LYGON STREET

(Street)

CARLTON SOUTH, VICTORIA 3053

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	644,247	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	09/12/2024	08/24/2026	Ordinary Shares	275,000	$0.06	D
Option (right to buy)	09/30/2025	09/30/2029	Ordinary Shares	2,666,667	$0.06	D
Option (right to buy)	(1)	09/30/2029	Ordinary Shares	5,333,333	$0.06	D
Option (right to buy)	12/02/2022	12/01/2026	Ordinary Shares	627,001	$0.6	D
Option (right to buy)	11/16/2023	12/01/2026	Ordinary Shares	627,001	$0.6	D
Option (right to buy)	11/16/2024	12/01/2026	Ordinary Shares	627,000	$0.6	D

Explanation of Responses:

1. Granted on December 16, 2024. 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027 provided Ms. Larkin is still a Director on such dates.

Remarks:

All exercise prices are in Australian dollars.

	/s/ Hester Larkin	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing for Radiopharm Theranostics (RADX) show for Hester Denise Larkin?

The Form 3 shows Hester Denise Larkin’s initial beneficial ownership in Radiopharm Theranostics, including ordinary shares and multiple stock option awards, establishing her baseline equity position as a director without reporting any recent share purchases or sales.

How many Radiopharm Theranostics ordinary shares does Hester Denise Larkin hold directly?

Hester Denise Larkin directly holds 644,247 ordinary shares of Radiopharm Theranostics. This direct ownership sits alongside several option grants, giving her both current share exposure and additional potential ownership through future option exercises.

What are the main option grants reported for Hester Denise Larkin at Radiopharm Theranostics (RADX)?

She holds options to buy ordinary shares at $0.06 and $0.60 per share, including 275,000 underlying shares at $0.06 expiring August 24, 2026 and 5,333,333 underlying shares at $0.06 expiring September 30, 2029, plus several tranches at $0.60 expiring December 1, 2026.

How do the 2024 option grants for RADX vest for director Hester Denise Larkin?

A December 16, 2024 grant provides 2,666,667 options vesting on September 30, 2026 and 2,666,666 options vesting on September 30, 2027. Vesting is conditioned on Ms. Larkin continuing to serve as a director on those specific vesting dates.

Does this Radiopharm Theranostics Form 3 show any insider buying or selling of RADX stock?

No, this Form 3 does not show insider buying or selling. It only lists Hester Denise Larkin’s existing holdings in ordinary shares and unexercised options, serving as an initial beneficial ownership snapshot rather than a record of recent trades.

What are the expiration dates of Hester Denise Larkin’s key options in Radiopharm Theranostics?

Key options include a 275,000-share grant at $0.06 expiring August 24, 2026, several $0.60 grants expiring December 1, 2026, and a large $0.06 grant over 5,333,333 underlying shares expiring September 30, 2029, providing long-dated equity exposure.